Cerus Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Rhea-AI Summary

Cerus Corporation (Nasdaq: CERS) will announce its Q4 and full year 2020 financial results on February 25, 2021, post-market close. A conference call is scheduled for 4:30 PM ET the same day, where management will discuss the financial results and provide a business overview and outlook. Interested parties can access the call via the Investor Relations page or by phone. A replay will be available shortly after the call.

Cerus focuses on ensuring safe blood supply through the INTERCEPT Blood System, which has received both CE Mark and FDA approval.

Positive

• Cerus aims to become a leading global blood products company.
• INTERCEPT Blood System approved by both CE and FDA for platelet and plasma components.
• Full year 2020 financial results are anticipated, indicating business growth.

Negative

• None.

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2020 financial results will be released on Thursday, February 25, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on Cerus’ website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 1267389. The replay will be available approximately three hours after the call through March 11, 2021.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Based in Concord, California, our employees are dedicated to deploying and supplying vital technologies and pathogen-protected blood components for blood centers, hospitals and ultimately patients who rely on safe blood. With the INTERCEPT Blood System, we are focused on protecting patients by delivering the full complement of reliable products and expertise for transfusion medicine. Cerus develops and markets the INTERCEPT Blood System and remains the only company in the blood transfusion space to earn both CE Mark and FDA approval for pathogen reduction of both platelet and plasma components. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005117/en/

FAQ

When will Cerus Corporation release its Q4 2020 financial results?

Cerus Corporation will release its Q4 2020 financial results on February 25, 2021, after the market closes.

What time is the Cerus Corporation conference call?

The Cerus Corporation conference call is scheduled for 4:30 PM ET on February 25, 2021.

How can I listen to the Cerus Corporation conference call?

You can listen to the Cerus Corporation conference call via the Investor Relations page on their website or by calling (866) 235-9006 for the U.S. and (631) 291-4549 for international access.

What is the INTERCEPT Blood System?

The INTERCEPT Blood System is a technology developed by Cerus Corporation designed to ensure the safety of blood components through pathogen reduction.